Eligard prostate cancer product to be launched in Germany

Published: 4-May-2004

US speciality pharmaceutical company Atrix Laboratories has announced that Eligard 7.5mg and Eligard 22.5mg (leuprolide acetate for injectable suspension) one- and three-month sustained release products have been launched in Germany by Yamanouchi.


US speciality pharmaceutical company Atrix Laboratories has announced that Eligard 7.5mg and Eligard 22.5mg (leuprolide acetate for injectable suspension) one- and three-month sustained release products have been launched in Germany by Yamanouchi.

Eligard is indicated for the palliative treatment of advanced prostate cancer.

In early December 2003 and early January 2004, MediGene received marketing authorisation for one-month Eligard and three-month Eligard products respectively. In early 2004, Atrix and MediGene signed a pan-European marketing agreement with Yamanouchi. Yamanouchi will also be responsible for achieving additional marketing authorisations in concerned Member States throughout Europe under a Mutual Recognition process.

'We are pleased to have Eligard competing in Germany, the third largest market in the world for this type of treatment,' said David R. Bethune, chairman and ceo at Atrix. 'We look forward to other European approvals and launches over the next several years.'

  

You may also like